VETOQUINOL (8JM) Stock Price & Analysis
8JM Stock Chart & Stats
- Day’s Range
- EUR 86.90 - EUR 86.90
- 52-Week Range
- EUR 65.30 - EUR 89.70
- Previous Close
- EUR 86.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 1.01B
- Enterprise Value
- EUR 599.57M
- Total Cash (Recent Filing)
- EUR 235.20M
- Total Debt (Recent Filing)
- EUR 12.35M
- Price to Earnings (P/E)
- 16.0
- Beta
- 0.27
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.07%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Minimal leverage materially reduces refinancing and solvency risk, giving Vetoquinol greater resilience during weaker trading conditions. Rising equity and assets also preserve flexibility to fund research, product development, operations, and shareholder distributions without relying heavily on external debt.
Resilient Profitability
Sustained net margins in the 9–12% range indicate that Vetoquinol has maintained meaningful earnings power across its animal-health portfolio. This profitability can support continued investment in development and commercialization while providing a durable buffer against moderate revenue volatility.
Positive Operating Cash Generation
Regularly positive operating and free cash flow demonstrates that the business generally converts its activities into internally generated funding. That supports reinvestment, dividends, and financial resilience, reducing dependence on borrowing to sustain the company over the coming quarters.
Bears Say
Weak Revenue Momentum
A recent top-line decline suggests that growth and market expansion are currently limited, which can constrain operating leverage and reduce the resources available for product investment. If this softness persists, it may offset the benefit of otherwise resilient margins and financial quality.
Uneven Cash Conversion
Moderate conversion of accounting profit into operating cash reduces the immediate funding available for reinvestment and distributions. The gap may reflect working-capital or timing effects, but persistent weakness would make reported earnings less dependable as a measure of usable financial capacity.
Margin Sustainability Risk
The unusually large 2025 margin improvement may not represent a fully repeatable change in the underlying business. If one-off benefits or product-mix effects fade, profitability could normalize toward earlier levels, limiting the durability of recent earnings improvement despite strong reported margins.
8JM FAQ
What was VETOQUINOL’s price range in the past 12 months?
What is VETOQUINOL’s market cap?
When is VETOQUINOL’s upcoming earnings report date?
How were VETOQUINOL’s earnings last quarter?
Is VETOQUINOL overvalued?
Does VETOQUINOL pay dividends?
What is VETOQUINOL’s EPS estimate?
How many shares outstanding does VETOQUINOL have?
What happened to VETOQUINOL’s price movement after its last earnings report?
Which hedge fund is a major shareholder of VETOQUINOL?
What is the TipRanks Smart Score and how is it calculated?
Company Description
VETOQUINOL
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Americas, and the Asia Pacific regions. The company's diverse product portfolio addresses crucial therapeutic areas, including mobility, pain management, and inflammation; dermatological care and hygiene; anti-parasitic treatments; udder health; infectious disease control; reproductive solutions; behavior modification; internal medicine; and cardiovascular-renal support. These offerings cater to a wide spectrum of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside companion animals like dogs. Founded in 1933, Vetoquinol S.A. is headquartered in Lure, France, and functions as a subsidiary of Soparfin SCA.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Matthieu Frechin
- Employees
- 2,526
- Website
- www.vetoquinol.com
- Address
- Magny-Vernois, Lure, BF, 70204, FR
VETOQUINOL (8JM) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| FR:VIRPVirbac SA |




